SUBSCRIBE
SUBSCRIBE
News   FDA

EU Backs Nycomed’s Daxas In Deadly Lung Disease; Drug Approval Could Spur Nycomed IPO

July 6, 2010 | 
1 min read
ZURICH July 6 (Reuters) - Nycomed's [NYCMD.UL] lung drug Daxas has won European Union backing to treat patients with chronic obstructive pulmonary disease, bringing to market the first new type of treatment for the disease in over a decade.
FDA Approvals Europe
MORE ON THIS TOPIC
Handmade signboard with Closed inscription and striped rope hanging on pin on bright red background
Company closure
Bespoke Startup EveryONE Folds 1 Week After Plausible Mechanism Guidance
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Dream Birds Flying Away, the birds flying out of a bird an open cage, the birds released from a cage, freedom concept. birds set free vector illustration.
Gene therapy
Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold
March 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration showing hurdles along a path ending in an arrow
Complete response letters
REGENXBIO’s Hunter Rejection Hinged on Inadequate Controls, Surrogate Endpoint
March 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
 · 
3 min read
 · 
Heather McKenzie